- scPharmaceuticals press release ( NASDAQ: SCPH ): Q2 GAAP EPS of -$0.35 misses by $0.05 .
- “The key highlight of the second quarter of 2022 was clearly the FDA’s acceptance of our FUROSCIX NDA and assignment of an October 8 th PDUFA date, and we are continuing to advance our commercial readiness activities in anticipation of a fourth quarter commercial launch, if approved,” stated John Tucker, chief executive officer of scPharmaceuticals. “At the same time, we added to the growing body of evidence demonstrating that there exists a significant unmet need in the treatment of heart failure patients, a significant source of hospital admissions and readmissions. We believe FUROSCIX, if approved, may represent a new paradigm in the treatment of heart failure with the potential to improve patient outcomes while generating significant cost savings for payers.”
For further details see:
scPharmaceuticals GAAP EPS of -$0.35 misses by $0.05